The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study.

ABSTRACT:

Background

Chronic myeloid leukemia is associated with a BCR/ABL oncoprotein inhibited by imatinib mesylate, the first tyrosine kinase inhibitor. Although experimental studies have clearly demonstrated the efficacy of imatinib, up-to-date data on its effectiveness at the population level are limited. Our study aims to assess the change in disease-specific survival for chronic myeloid leukemia after introducing tyrosine kinase inhibitors in first-line treatment.

Methods

This study analyzed data from two population-based cancer registries in Italy. Disease-specific survival for chronic myeloid leukemia cases diagnosed before and after the introduction of tyrosine kinase inhibitors (February 2002) were calculated up to 10 years. Hazard ratios were calculated using Cox regressio

SUBMITTER: Di Felice E 

PROVIDER: S-EPMC6219019 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature